贝伐珠单抗腹腔灌注治疗卵巢癌的研究现状
Progress of bevacizumab intraperitoneal instillation in the treatment of ovarian cancer
张志琪 1张卓 1刘倩欣 1向倩 1崔一民2
作者信息
- 1. 北京大学第一医院药学部,北京 100034
- 2. 北京大学第一医院药学部,北京 100034;北京大学第一医院临床药理研究所,北京 100034
- 折叠
摘要
血管内皮生长因子(VEGF)在卵巢癌组织中的表达与卵巢癌的恶性程度密切相关,可作为卵巢癌治疗的有效靶点.贝伐珠单抗作为靶向VEGF的单克隆抗体,可抑制肿瘤新生血管形成与肿瘤生长,临床中用于治疗卵巢癌、宫颈癌、转移性结直肠癌等恶性肿瘤.贝伐珠单抗腹腔灌注给药对于肿瘤患者恶性腹水具有良好疗效,可缓解患者临床症状.近年来,有研究探索了贝伐珠单抗腹腔灌注治疗卵巢癌的临床应用方法、治疗疗效以及相关药物不良反应,本文现就这一领域作一综述,旨在为卵巢癌的临床治疗提供参考.
Abstract
The expression of vascular endothelial growth factor(VEGF)in ovarian cancer tissues is closely related to the degree of malignancy of ovarian cancer,and can be an effective target for ovarian cancer treatment.Bevacizumab,as a monoclonal antibody targeting VEGF,can inhibit tumor neovascularization and tumor growth,and is used for the treatment of ovarian cancer,cervical cancer,metastatic colorectal cancer and other malignant tumors.Bevacizumab administered by intraperitoneal perfusion has good efficacy for malignant ascites in tumor patients,and can alleviate patients'clinical symptoms.In recent years,more studies have explored the clinical application method,therapeutic efficacy and related adverse effects of bevacizumab intraperitoneal instillation in the treatment of ovarian cancer,and this article is a review in this field,aiming to provide reference for the clinical treatment of ovarian cancer.
关键词
贝伐珠单抗/腹腔灌注/恶性肿瘤/合理用药Key words
bevacizumab/intraperitoneal perfusion/malignant tumors/rational drug use引用本文复制引用
基金项目
北京大学第一医院院内交叉临床研究专项基金资助项目(2022CR36)
国家自然科学基金资助项目(82073935)
国家自然科学基金资助项目(81973395)
国家自然科学基金资助项目(81872940)
北京市科技计划基金资助项目(Z191100007619038)
出版年
2024
国家科技期刊平台
NSTL
万方数据